Pharmafile Logo

News and Press Releases

Johnson & Johnson’s DARZALEX (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma Milestone is a testament to ten years of daratumumab experience and innovation, continuing...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: March 27, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials 27 March 2026 -- Cambridge, UK -- Positive...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2026

AstraZeneca
Medical.InformationUK@astrazeneca.com
PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA UK

CWOW 2026: Cambridge’s Grassroots Life Sciences Showcase Branches Out to Oxford & London

26 March 2026 -- Cambridge, UK -- Cambridge Wide Open Week (CWOW) returns 11–19 June 2026, sharing the spirit and buzz of the week-long,interactive festival with Oxford and London for...

Category: Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2026

o2h
info@o2h.com
Mill SciTech Park, Mill Lane Hauxton, Cambridge CB22 5HX

ADOA PROGRAM – PRESENTATION AT NANOS 2026

PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available One of PYC’s clinical-stage programs is an investigational...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2026

PYC Therapeutics
info@pyctx.com
6 Verdun Street, Nedlands, Western Australia 6009

SLAS Announces the Cohort for Innovation AveNEW at SLAS Europe 2026

Twelve emerging life science startups to showcase enabling technologies at the SLAS European Conference and Exhibition in Vienna, 19-21 May 2026 23 March 2026 -- Vienna, Austria -- SLAS, the...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 23, 2026

Society for Laboratory Automation and Screening
slas@slas.org
1301 West 22nd Street, Suite 708 Oak Brook, IL 60523 USA

Tilray Medical Announces Major Expansion of Medical Cannabis Portfolio in Australia

19 March 2026 -- New York, US and Sydney, Australia -- Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. today announced its...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 19, 2026

Tilray Medical
info@tilraymedical.com

BIO-Europe Spring 2026: Partnering Momentum Builds as Global Biopharma Leaders Set Course for Lisbon

16 March 2026 -- Munich, Germany -- The global biopharmaceutical community is preparing to gather in Lisbon, Portugal, for the 20th edition of BIO-Europe Spring, the premier springtime partnering conference...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 16, 2026

Informa
media@informa.com
5 Howick Place London SW1P 1WG UK

Kainova Therapeutics Announces Positive Phase I Results for DT-9081, an Oral EP4 Receptor Antagonist, in Advanced Solid Tumors

Phase I results demonstrate favorable safety, sustained target engagement, and early signs of anti-tumor activity Reinforce EP4 receptor antagonism as a validated, high-value strategy to overcome immunotherapy resistance. 10 March...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 10, 2026

Kainova Therapeutics
contact@kainovatx.com
7171 Frederick Banting Montreal, QC H4S 1Z9 Canada

MAPS Sends Expert Delegation to United Nations Commission on Narcotic Drugs

MAPS delegation includes senior researchers, policy experts, and Veterans from the US, Europe, Australia, and the Middle East The CND is a central drug policy-making body in the UN, playing...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

The Multidisciplinary Association for Psychedelic Studies (MAPS)
media@maps.org
3141 Stevens Creek Blvd #40563, San Jose, CA 95117

Medidata Expands Partnership with The Menarini Group, Deploying Medidata’s Study Build AI Technology to Accelerate Global Oncology Pipeline

Fourteen-year collaboration enters a new phase as Menarini evolves its use of the Medidata Platform, combining established clinical workflows with AI to power its global oncology pipeline 9 March 2026...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Medidata
helpdesk@mdsol.com
350 Hudson Street New York, NY 10014 USA

European Commission approves AKEEGA (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with BRCA1/2-mutated metastatic hormone-sensitive prostate cancer (mHSPC)

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall survival versus standard...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 9, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026

Dosimetry data from the Phase 3 ECLIPSE substudy demonstrated favorable organ radiation absorbed doses supporting administration of 7.4 GBq for up to six cycles 26 February 2026 -- Massachusetts, US...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 3, 2026

Curium Pharma
contactus@curiumpharma.com
Perceptive 55 Blue Sky Drive Burlington Massachusetts 01803 United States

OBN Invites Life Science Leaders to Celebrate 20 Years of BioTrinity

Featuring keynotes from: Steve Bates, Executive Chair at the Office for Life Sciences, Lawrence Tallon, CEO at the MHRA & Maria Koufali, Life Sciences Industry Director at the NIHR, click...

Category: Other, Pharmaceutical
Posted: March 3, 2026

OBN
info@obn.org.uk
Unit 6 Library Avenue, Harwell, Didcot, OX11 0SG, UK

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening

• Drs Giulia Kennedy, Arnold Levine, John Sninsky, Martin Goldberg and Prof Tin Tin Su join SAB• Follows close of initial funding round with investment from Stephen Quake and Jay...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 2, 2026

Wisdom Bioscience
info@wisdombioscience.com

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3 Data highlight the potential of this first-in-class next-generation T-cell engager to expand the role...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 26, 2026

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG